Cargando…
Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy
OBJECTIVE: Brain atrophy has the potential to become a biomarker for severity of radiation-induced side-effects. Particularly brain tumour patients can show great MRI signal changes over time caused by e.g. oedema, tumour progress or necrosis. The goal of this study was to investigate if such change...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901471/ https://www.ncbi.nlm.nih.gov/pubmed/33786695 http://dx.doi.org/10.1007/s10334-021-00922-3 |
_version_ | 1784664374922706944 |
---|---|
author | Gommlich, A. Raschke, F. Petr, J. Seidlitz, A. Jentsch, C. Platzek, I. van den Hoff, J. Kotzerke, J. Beuthien-Baumann, B. Baumann, M. Krause, M. Troost, E. G. C. |
author_facet | Gommlich, A. Raschke, F. Petr, J. Seidlitz, A. Jentsch, C. Platzek, I. van den Hoff, J. Kotzerke, J. Beuthien-Baumann, B. Baumann, M. Krause, M. Troost, E. G. C. |
author_sort | Gommlich, A. |
collection | PubMed |
description | OBJECTIVE: Brain atrophy has the potential to become a biomarker for severity of radiation-induced side-effects. Particularly brain tumour patients can show great MRI signal changes over time caused by e.g. oedema, tumour progress or necrosis. The goal of this study was to investigate if such changes affect the segmentation accuracy of normal appearing brain and thus influence longitudinal volumetric measurements. MATERIALS AND METHODS: T1-weighted MR images of 52 glioblastoma patients with unilateral tumours acquired before and three months after the end of radio(chemo)therapy were analysed. GM and WM volumes in the contralateral hemisphere were compared between segmenting the whole brain (full) and the contralateral hemisphere only (cl) with SPM and FSL. Relative GM and WM volumes were compared using paired t tests and correlated with the corresponding mean dose in GM and WM, respectively. RESULTS: Mean GM atrophy was significantly higher for full segmentation compared to cl segmentation when using SPM (mean ± std: ΔV(GM,full) = − 3.1% ± 3.7%, ΔV(GM,cl) = − 1.6% ± 2.7%; p < 0.001, d = 0.62). GM atrophy was significantly correlated with the mean GM dose with the SPM cl segmentation (r = − 0.4, p = 0.004), FSL full segmentation (r = − 0.4, p = 0.004) and FSL cl segmentation (r = -0.35, p = 0.012) but not with the SPM full segmentation (r = − 0.23, p = 0.1). CONCLUSIONS: For accurate normal tissue volume measurements in brain tumour patients using SPM, abnormal tissue needs to be masked prior to segmentation, however, this is not necessary when using FSL. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10334-021-00922-3. |
format | Online Article Text |
id | pubmed-8901471 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-89014712022-03-15 Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy Gommlich, A. Raschke, F. Petr, J. Seidlitz, A. Jentsch, C. Platzek, I. van den Hoff, J. Kotzerke, J. Beuthien-Baumann, B. Baumann, M. Krause, M. Troost, E. G. C. MAGMA Research Article OBJECTIVE: Brain atrophy has the potential to become a biomarker for severity of radiation-induced side-effects. Particularly brain tumour patients can show great MRI signal changes over time caused by e.g. oedema, tumour progress or necrosis. The goal of this study was to investigate if such changes affect the segmentation accuracy of normal appearing brain and thus influence longitudinal volumetric measurements. MATERIALS AND METHODS: T1-weighted MR images of 52 glioblastoma patients with unilateral tumours acquired before and three months after the end of radio(chemo)therapy were analysed. GM and WM volumes in the contralateral hemisphere were compared between segmenting the whole brain (full) and the contralateral hemisphere only (cl) with SPM and FSL. Relative GM and WM volumes were compared using paired t tests and correlated with the corresponding mean dose in GM and WM, respectively. RESULTS: Mean GM atrophy was significantly higher for full segmentation compared to cl segmentation when using SPM (mean ± std: ΔV(GM,full) = − 3.1% ± 3.7%, ΔV(GM,cl) = − 1.6% ± 2.7%; p < 0.001, d = 0.62). GM atrophy was significantly correlated with the mean GM dose with the SPM cl segmentation (r = − 0.4, p = 0.004), FSL full segmentation (r = − 0.4, p = 0.004) and FSL cl segmentation (r = -0.35, p = 0.012) but not with the SPM full segmentation (r = − 0.23, p = 0.1). CONCLUSIONS: For accurate normal tissue volume measurements in brain tumour patients using SPM, abnormal tissue needs to be masked prior to segmentation, however, this is not necessary when using FSL. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10334-021-00922-3. Springer International Publishing 2021-03-31 2022 /pmc/articles/PMC8901471/ /pubmed/33786695 http://dx.doi.org/10.1007/s10334-021-00922-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Gommlich, A. Raschke, F. Petr, J. Seidlitz, A. Jentsch, C. Platzek, I. van den Hoff, J. Kotzerke, J. Beuthien-Baumann, B. Baumann, M. Krause, M. Troost, E. G. C. Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy |
title | Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy |
title_full | Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy |
title_fullStr | Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy |
title_full_unstemmed | Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy |
title_short | Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy |
title_sort | overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901471/ https://www.ncbi.nlm.nih.gov/pubmed/33786695 http://dx.doi.org/10.1007/s10334-021-00922-3 |
work_keys_str_mv | AT gommlicha overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy AT raschkef overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy AT petrj overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy AT seidlitza overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy AT jentschc overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy AT platzeki overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy AT vandenhoffj overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy AT kotzerkej overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy AT beuthienbaumannb overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy AT baumannm overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy AT krausem overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy AT troostegc overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy |